Compare AbbVie Inc (ABBV) vs Hut 8 Corp (HUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Hut 8 Corp — how do they compare? AbbVie Inc trades at $248.98 (market cap $441.94B), while Hut 8 Corp trades at $92.76 (market cap $10.94B). The key difference: AbbVie Inc is far larger — about 40.4× Hut 8 Corp's market cap, and AbbVie Inc pays a 2.77% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals.
| ABBV | HUT | |
|---|---|---|
Market Cap | $441.94B | $10.94B |
Sector | Health | Technology |
52-Week High | $263.58 | $133.02 |
52-Week Low | $197.38 | $21.37 |
Enterprise Value | $506.19B | $18.38B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
HUT trades at $88.59, down 2.27% today amid bearish technical signals and mixed quarterly earnings. The stock faces headwinds from negative net income margins and cash burn, but maintains strong analyst support with a 93.75% buy rating and a $165.11 consensus price target. Recent news highlights institutional accumulation and a strategic pivot to AI data centers, backed by a $26.6 billion contracted backlog.
Outlook hinges on execution of AI infrastructure projects, offering substantial upside if targets are met, but high valuation multiples and persistent losses pose risks. Investors must weigh growth potential against financial sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
